← Leaderboards
Yawei Ni
Nanotherapeutics, Inc.
$3,837,115
Attributed
$5,622,853
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,622,853 · 5
By mechanism
R44$3,571,476 · 1
R43$2,051,377 · 4
Top collaborators
- James Forrest Kirk5 shared
Most similar at Nanotherapeutics, Inc.
Same institution · by research overlap
- James Forrest Kirk$1,785,738
- Ronald Cobb$296,331
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesImmunogenicityClinical ResearchBaseAntigensAnimalsPre-ClinicalVirusAdjuvantImmune ResponseEpidemicCyclic GmpAcidsPolysaccharidesAnimal ModelToxicologyGenerationsFuturePlantsDisease OutbreaksSafetyResponseSeriesBacteria
Grant awards (12)
Development of a low molecular weight synthetic Vi conjugate vaccine for salmonella typhi$296,436
R43 · FY2025 · AI · contact PI
Development of a low molecular weight synthetic Vi conjugate vaccine for salmonella typhi$286,507
R43 · FY2024 · AI · contact PI
GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine$997,966
R44 · FY2015 · AI
A novel broad-spectrum influenza vaccine$290,634
R43 · FY2015 · AI · contact PI
GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine$997,804
R44 · FY2014 · AI
A novel broad-spectrum influenza vaccine$300,258
R43 · FY2014 · AI · contact PI
GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine$996,995
R44 · FY2013 · AI
GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine$289,356
R44 · FY2012 · AI
A universal influenza vaccine by dual-domain fusion with a novel carrier protein$277,928
R43 · FY2012 · AI · contact PI
A universal influenza vaccine by dual-domain fusion with a novel carrier protein$300,000
R43 · FY2011 · AI · contact PI
GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine$289,355
R44 · FY2011 · AI
Development of A Synthetic Typhoid Fever Vaccine as A Substitution of Vi Vaccine$299,614
R43 · FY2010 · AI · contact PI